AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2182032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose insulin regimen (mainly intermediate acting insulin before breakfast and dinner)
Number of subjects: 10
Study 2182032 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose insulin regimen (regular insulin preprandially with intermediate acting insulin at bedtime)
Number of subjects: 10
Study 2182032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose insulin regimen
Number of subjects: 10
Study 2182032 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose insulin regimen
Number of subjects: 10
Study 2182032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose insulin regimen and 4-dose insulin regimen
Number of subjects: 10
Study 396655 — intervention group
Group type: EXPERIMENTAL
Intervention: LS 519 (75 mg/day)
Number of subjects: 64
Study 396655 — intervention group
Group type: EXPERIMENTAL
Intervention: LS 519 (150 mg/day)
Number of subjects: 64
Study 396655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 396655 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (300 mg/day)
Number of subjects: 64
Study 31937907 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (1000 kcal/day for women and 1200 kcal/day for men)
Number of subjects: 109
Study 31937907 — intervention group
Group type: EXPERIMENTAL
Intervention: Week-on-week-off energy restriction (alternating between energy restriction and habitual diet)
Number of subjects: 109
Study 31937907 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 energy restriction (500 kcal/day for women and 600 kcal/day for men on modified fast days)
Number of subjects: 109
Study 31937907 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 109
Study 30611977 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application consisting of personalized feedback, risk assessment and self-monitoring
Number of subjects: 977
Study 28514205 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT+endostar
Number of subjects: 0
Study 28514205 — intervention group
Group type: COMPARATOR
Intervention: CRT only
Number of subjects: 0
Study 25514821 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-strengthening program (6 months, 3 times a week)
Number of subjects: 109
Study 25514821 — intervention group
Group type: COMPARATOR
Intervention: Comparable handball training program (no specific upper-body strength training)
Number of subjects: 109
Study 25514821 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-strengthening program
Number of subjects: 109
Study 24226711 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/d for 3 days)
Number of subjects: 200
Study 21121988 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm NaF
Number of subjects: 50
Study 21121988 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm AmF
Number of subjects: 50
Study 21121988 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm MFP
Number of subjects: 50
Study 21121988 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm MFP and xylitol
Number of subjects: 50
Study 21121988 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice
Number of subjects: 50
Study 19213225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid absorbing gut suture
Number of subjects: 8
Study 19213225 — intervention group
Group type: COMPARATOR
Intervention: Tissue adhesive (2-octylethylcyanoacrylate)
Number of subjects: 8
Study 19213225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 8
Study 17556414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-chelation therapy with calcium disodium EDTA
Number of subjects: 116
Study 17556414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 17556414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-chelation therapy
Number of subjects: 116
Study 17556414 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated chelation therapy
Number of subjects: 116
Study 14764176 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0
Study 14764176 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (mainly amiodarone)
Number of subjects: 0
Study 11250998 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 1772
Study 11250998 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 1772
Study 11250998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1772
Study 9337166 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous port insertion
Number of subjects: 119
Study 9337166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-valve effect as a primary complication
Number of subjects: 119
Study 9337166 — intervention group
Group type: EXPERIMENTAL
Intervention: Port-related venous thrombosis as a subsequent complication
Number of subjects: 119
Study 9337166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-valve effect as a risk factor for venous thrombosis
Number of subjects: 119
Study 8202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 12
Study 8202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg with flurbiprofen 200 mg
Number of subjects: 12
Study 8202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg
Number of subjects: 12
Study 8202898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2438319 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex (isoprinosine) therapy for 20 weeks
Number of subjects: 25
Study 2438319 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 20 weeks
Number of subjects: 25
Study 29979479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational football
Number of subjects: 42
Study 29979479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 42
Study 29979479 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 42
Study 27809793 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program
Number of subjects: 70549
Study 27809793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70549
Study 23983269 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometry (VIS)
Number of subjects: 16
Study 23983269 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-oriented incentive spirometry (FIS)
Number of subjects: 16
Study 24237190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 11
Study 24237190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium plus sertraline
Number of subjects: 11
Study 24237190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium alone
Number of subjects: 11
Study 24237190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21168715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 25
Study 21168715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 25
Study 21168715 — intervention group
Group type: COMPARATOR
Intervention: CNI discontinuation
Number of subjects: 25
Study 18977831 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar plate
Number of subjects: 30
Study 18977831 — intervention group
Group type: COMPARATOR
Intervention: Dorsal Pi-plate
Number of subjects: 30
Study 16648225 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 19
Study 16648225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14714846 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated post-soldering procedure
Number of subjects: 36
Study 14714846 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple firing
Number of subjects: 36
Study 14714846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 11049917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.2 mg/kg IV bolus, followed by infusion
Number of subjects: 60
Study 11049917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium with propofol
Number of subjects: 60
Study 11049917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 60
Study 11049917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg IV, followed by infusion
Number of subjects: 60
Study 11049917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 60
Study 11049917 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 8831436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interpersonal psychotherapy and tricyclic antidepressant (nortriptyline for elderly, imipramine for midlife) during acute-phase therapy
Number of subjects: 362
Study 8831436 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with the same therapy
Number of subjects: 362
Study 1434328 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 265
Study 1434328 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 265
Study 1434328 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 265
Study 1434328 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 265
Study 1434328 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 265
Study 3883918 — intervention group
Group type: EXPERIMENTAL
Intervention: Seatone (green-lipped mussel extract)
Number of subjects: 35
Study 3883918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31314966 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline testing plus annual testing, eligibility for universal ART, and patient-centered care (intervention group)
Number of subjects: 150395
Study 31314966 — intervention group
Group type: COMPARATOR
Intervention: Baseline HIV and multidisease testing and national guideline-restricted ART (control group)
Number of subjects: 150395
Study 29777115 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming training
Number of subjects: 9
Study 29777115 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 9
Study 27118441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + PX-866 (arm A)
Number of subjects: 85
Study 27118441 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab alone (arm B)
Number of subjects: 85
Study 24559035 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (MI)
Number of subjects: 0
Study 24559035 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 0
Study 24559035 — intervention group
Group type: COMPARATOR
Intervention: Counselor Satisfaction Ratings
Number of subjects: 0
Study 22651541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol 250/50 mcg (FSC)
Number of subjects: 214524
Study 22651541 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergics (ACs)
Number of subjects: 214524
Study 19487628 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-FDA advisory trends
Number of subjects: 792
Study 17194834 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 300
Study 17194834 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 300
Study 14693626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2.5 mg (group B)
Number of subjects: 60
Study 14693626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 2.5 mg (group R)
Number of subjects: 60
Study 14693626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine 2.5 mg (group L)
Number of subjects: 60
Study 11668132 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 100 microgram
Number of subjects: 25
Study 11668132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9520073 — intervention group
Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR)
Number of subjects: 12
Study 9520073 — intervention group
Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR) after standard breakfast
Number of subjects: 12
Study 9520073 — intervention group
Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR) in fasted condition
Number of subjects: 12
Study 9520073 — intervention group
Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR) with food
Number of subjects: 12
Study 7737238 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tiracizine hydrochloride
Number of subjects: 8
Study 7737238 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tiracizine hydrochloride
Number of subjects: 8
Study 7737238 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tiracizine hydrochloride
Number of subjects: 8
Study 7737238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiracizine (all doses)
Number of subjects: 8
Study 7737238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiracizine (serum concentrations about 80 ng/ml)
Number of subjects: 8
Study 2537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus diuretics (n = 72)
Number of subjects: 142
Study 2537562 — intervention group
Group type: COMPARATOR
Intervention: Digoxin plus diuretics (n = 70)
Number of subjects: 142
Study 31748939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-release methadone treatment
Number of subjects: 114
Study 30079791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 154
Study 30079791 — intervention group
Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 154
Study 27511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA)
Number of subjects: 200
Study 27511904 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 200
Study 27511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DA and UC
Number of subjects: 200
Study 26179184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropic therapy (Milrinone in 84.8% and Dobutamine in 15.2%)
Number of subjects: 197
Study 26179184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropic therapy as a bridge to transplant/LVAD
Number of subjects: 197
Study 24119693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance rate (LCR)
Number of subjects: 50
Study 24119693 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation (ScvO2)
Number of subjects: 50
Study 24119693 — intervention group
Group type: COMPARATOR
Intervention: LCR
Number of subjects: 50
Study 24119693 — intervention group
Group type: COMPARATOR
Intervention: LCR and ScvO2
Number of subjects: 50
Study 20833488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary soy supplementation (90 mg of isoflavone)
Number of subjects: 60
Study 20833488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (1mg estradiol and 0.5mg norethisterone acetate)
Number of subjects: 60
Study 20833488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18408610 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH; Ritalin; 20 mg)
Number of subjects: 8
Study 18408610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 20 mg)
Number of subjects: 8
Study 15651723 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen of 2 mg trichlormethiazide
Number of subjects: 85
Study 15651723 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily regimen of 2 mg trichlormethiazide
Number of subjects: 85
Study 12923219 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation
Number of subjects: 13
Study 12923219 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA isomer trans-10, cis-12
Number of subjects: 13
Study 12923219 — intervention group
Group type: COMPARATOR
Intervention: CLA supplementation
Number of subjects: 13
Study 10891662 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine for 18 months
Number of subjects: 123
Study 10891662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 10891662 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine
Number of subjects: 123
Study 8654630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 20
Study 8654630 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery)
Number of subjects: 20
Study 1846783 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET) infusion at low dose (0.5 ng/min/100 ml forearm tissue)
Number of subjects: 25
Study 1846783 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET) infusion at high doses (25 and 50 ng/min/100 ml forearm tissue)
Number of subjects: 25
Study 1846783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (6 micrograms/min/100 ml forearm tissue)
Number of subjects: 25
Study 1846783 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 micrograms/min/100 ml forearm tissue)
Number of subjects: 25
Study 1846783 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.6 micrograms/min/100 ml forearm tissue)
Number of subjects: 25
Study 1846783 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (16 micrograms/min/100 ml forearm tissue)
Number of subjects: 25
Study 6357805 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse.
Number of subjects: 119
Study 6357805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin.
Number of subjects: 119
Study 6357805 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse (group A).
Number of subjects: 119
Study 6357805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin (group AV).
Number of subjects: 119
Study 6357805 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses (group A).
Number of subjects: 119
Study 30606237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) granules (4.9 g twice daily) plus salmeterol/fluticasone propionate combination for 12 weeks
Number of subjects: 60
Study 30606237 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo plus salmeterol/fluticasone propionate combination for 12 weeks
Number of subjects: 60
Study 26300464 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with ingenol mebutate gel (0.015% and 0.05%)
Number of subjects: 199
Study 26300464 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with ingenol mebutate gel (0.015% and 0.05%)
Number of subjects: 199
Study 23903802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 26
Study 23903802 — intervention group
Group type: COMPARATOR
Intervention: Oral calcitriol
Number of subjects: 26
Study 22932160 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (AT+RT)
Number of subjects: 58
Study 22932160 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 58
Study 19574868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound machine models with the simplest ergonomic design and user interface
Number of subjects: 26
Study 19574868 — intervention group
Group type: EXPERIMENTAL
Intervention: Largest, most complex ultrasound machine
Number of subjects: 26
Study 19574868 — intervention group
Group type: EXPERIMENTAL
Intervention: All machine models
Number of subjects: 26
Study 16466169 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiji Recipe (FJR) and chemotherapy
Number of subjects: 102
Study 16466169 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 102
Study 12504039 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionation radiation therapy (Arm A)
Number of subjects: 192
Study 12504039 — intervention group
Group type: EXPERIMENTAL
Intervention: Split‐course accelerated hyperfractionated RT (Arm B)
Number of subjects: 192
Study 12504039 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionation RT plus concomitant chemotherapy (Arm C)
Number of subjects: 192
Study 10817001 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanyl (bolus dose of 50 micrograms.kg‐1 and continuous infusion of 0.50 microgram.kg‐1.min‐1)
Number of subjects: 100
Study 10817001 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (bolus dose of 5 micrograms.kg‐1 and continuous infusion of 0.16 microgram.kg‐1.min‐1)
Number of subjects: 100
Study 8776186 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated group (Group H)
Number of subjects: 33
Study 8776186 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 33
Study 8776186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 1498061 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 intravenous CMF courses (cyclophosphamide, methotrexate, 5FU) - 113 patients
Number of subjects: 228
Study 1498061 — intervention group
Group type: COMPARATOR
Intervention: 3 courses of MTV (mitomycin C, thiotepa, vindesine) plus 3 courses of EVM (epirubicin, vincristine, methotrexate) - 115 patients
Number of subjects: 228
Study 6494455 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 20
Study 6494455 — intervention group
Group type: COMPARATOR
Intervention: Megluminamidotrizoate
Number of subjects: 20
Study 30865632 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) with sulfadoxine‐pyrimethamine plus amodiaquine given once a month for 5 months
Number of subjects: 4546
Study 30865632 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 4546